(VIANEWS) – Pacific Biosciences of California (NASDAQ: PACB) stock prices fell 34.72% over 21 sessions from EUR5.53 to EUR3.61, from February 29th to March 14th. This decline occurred even as the wider NASDAQ market, dropped only 0.27% to EUR16,384.47; its stock now trading 75.19% below its 52-week high of EUR14.55.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. is a biotechnology company that specializes in genomic sequencing solutions to address genetically complex problems. This company provides sequencing systems, consumable products, reagent kits, and sequencing services to various customers, including academic institutions, research facilities, government agencies, pharmaceutical firms, and agricultural businesses. Products offered by Sequenom include SMRT technology, long-read sequencing solutions and short-read sequencing approaches, as well as related reagents and consumables. Pacific Biosciences of California, Inc. markets its products through an international sales force and distribution partners in various regions worldwide, while also having strategic alliances with companies like Invitae Corporation and Radboud University Medical Center. Established in 2000 and located in Menlo Park, California.
Yearly Analysis
Yearly Peak and Bottom Value: Pacific Biosciences of California’s current stock price is below its 52-week low of EUR4.00, suggesting it has experienced underperformance over the past year.
Anticipated Sales Growth: Anticipated sales growth for this year and next is anticipated at 19.2% and 46.5%, providing an optimistic view for revenue expansion at the company.
Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA): Pacific Biosciences of California has an EBITDA score of 7.44, signalling positive net income and sound financial condition.
Technical Analysis
Pacific Biosciences of California (PACB) has experienced a decline in stock value, with its current price falling below both its 50-day and 200-day moving averages. Furthermore, its last reported volume – 4,328,310 – represents 50.74% less investor interest in its shares compared to their average volume of 8,591,410. This suggests a lack of enthusiasm from investors regarding this stock.
Pacific Biosciences of California has experienced an increase in intraday variation averages over the last week, month, and quarter; its highest average volatility amplitude was 3.27% for each of these periods – this week at 3.27%, 5.055% last month and 4.766% last quarter.
Furthermore, Pacific Biosciences of California’s stock is currently overbought (>=80), which could indicate that it may experience a correction soon.
Pacific Biosciences of California’s current stock performance appears to be negative and investors should exercise extreme caution and monitor it in the coming weeks and months.
Quarter Analysis
Pacific Biosciences of California has seen impressive sales growth, with an incredible current quarter growth rate of 46.2% and estimates for this and subsequent quarters at 25% and 7.1%, respectively. Furthermore, year-on-year quarterly revenue growth stands at an incredible 113.3% year over year; yielding 200.52M trailing revenues and suggesting strong and consistent revenue growth over the past year as an indication of healthy and expanding business operations.
Equity Analysis
Pacific Biosciences of California currently boasts a negative trailing twelve month EPS of EUR-1.21, suggesting it is currently unprofitable. Furthermore, its negative return on equity of -48.53% over twelve trailing months suggests it does not generate positive returns for investors who invest in its stock. Investors should take care in reviewing these financial performance indicators before making investment decisions.
More news about Pacific Biosciences of California (PACB).
